Getting the most out of technology for multichannel marketingWhile every pharma company recognises the potential of multichannel marketing to optimize its engagement with prescribers, many are Share XGetting the most out of technology for multichannel marketinghttps://pharmaphorum.com/whitepapers/getting-the-most-out-of-technology-for-multichannel-marketing/
Is pharma brand marketing dead or has it just arrived?As the pharma industry scrutinizes every aspect of its operations in the drive for greater efficiency, the processes Share XIs pharma brand marketing dead or has it just arrived?https://pharmaphorum.com/whitepapers/is-pharma-brand-marketing-dead-or-has-it-just-arrived/
How pharma Tweetchats can drive healthcare innovationDuring the course of 2013 Boehringer Ingelheim explored the use of multi-way communication on Twitter, via Tweetchats, as Share XHow pharma Tweetchats can drive healthcare innovationhttps://pharmaphorum.com/whitepapers/how-pharma-tweetchats-can-drive-healthcare-innovation/
Doctor networks: The rules of engagement for pharmaAs online doctor networks have grown they have also developed their own rules around how members interact, what Share XDoctor networks: The rules of engagement for pharmahttps://pharmaphorum.com/whitepapers/the-rules-of-engagement-for-pharma/
The Healthcare Meetings Forum 2013Healthcare meetings are experiencing a time of change, as new compliance regulations, the rise of digital and the Share XThe Healthcare Meetings Forum 2013https://pharmaphorum.com/whitepapers/the-healthcare-meetings-forum-2013/
Customer-centric multi-channel pharma marketingMulti-channel marketing is again a hot topic in the pharma industry, with its promise of improved productivity yielding Share XCustomer-centric multi-channel pharma marketinghttps://pharmaphorum.com/whitepapers/customer-centric-multi-channel-pharma-marketing/
How to effectively engage in the rare disease spaceEngaging with the relevant healthcare stakeholders for pharma company sales forces increasingly requires on-going adapatation and new skills, Share XHow to effectively engage in the rare disease spacehttps://pharmaphorum.com/whitepapers/how-to-effectively-engage-in-the-rare-disease-space/
Outcomes shape the new payer networks for pharmaThe definition of the payer and the way in which healthcare spending decisions are made is changing, as Share XOutcomes shape the new payer networks for pharmahttps://pharmaphorum.com/whitepapers/outcomes-shape-the-new-payer-networks-for-pharma/
